IL-17 Inhibitor Deal Benchmarks

Median Upfront

$400M

Range: $220M - $573M

Total Deal Value

$2.1B

Range: $1.4B - $2.9B

Royalty Rate

6.6% - 13.1%

Tiered up to 17.1%

Dev Milestones

$350M

Range: $235M - $465M

Model Your Deal

Market Analysis

IL-17 inhibitors have become the gold standard for plaque psoriasis treatment, with secukinumab, ixekizumab, and bimekizumab generating $10B+ in combined annual revenue. Phase 2 IL-17 inhibitor deals carry a median total deal value of $2.1B, with upfront payments of $400M. The validated pathway, large addressable population (7.5M US psoriasis patients), and expanding indication potential (psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa) sustain robust deal activity.

Milestone structures for IL-17 inhibitor deals allocate $350M to development milestones, $437M to regulatory milestones, and $961M to commercial milestones. The 19/81 upfront/milestone split reflects the well-defined clinical development pathway with PASI 75/90/100 as established primary endpoints.

Royalty rates for IL-17 inhibitor licensing range from 6.6% to 13.1% at the base tier. Differentiation factors include IL-17A versus IL-17A/F versus IL-17C selectivity, dosing frequency, immunogenicity profile, and potential for combination with other pathways. Next-generation IL-17 inhibitors with oral bioavailability or improved convenience (fewer injections, auto-injector delivery) command the highest premiums.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for IL-17 inhibitor licensing?

Phase 2 IL-17 inhibitor deals average $400M upfront with $2.1B total deal value. The validated pathway and established commercial precedent ($10B+ market) provide a strong foundation for deal negotiations.

How do IL-17A vs. IL-17F inhibitor deals differ?

Dual IL-17A/F inhibitors (like bimekizumab) have demonstrated superior PASI responses compared to IL-17A-only inhibitors, commanding 10-15% higher deal premiums. IL-17C inhibitors represent a differentiated approach targeting keratinocyte-driven inflammation with potentially superior safety profiles.

What is the biosimilar impact on IL-17 inhibitor deals?

Secukinumab biosimilars are expected from 2025-2027, creating pricing pressure on first-generation IL-17 inhibitors. However, next-generation IL-17 inhibitors with differentiated mechanisms, improved convenience, or expanded indication packages maintain premium deal terms. Biosimilar risk is factored into royalty term negotiations.

Which indications beyond psoriasis drive IL-17 deal value?

Key expansion indications include psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and non-infectious uveitis. Multi-indication IL-17 programs can command 20-30% higher total deal values versus psoriasis-only programs due to the expanded commercial opportunity.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

IL-17 Inhibitor Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Dermatology Deal Overview

JAK Inhibitor Derm Deals

Phase 2 Deal Benchmarks

Small Molecule Deals

Ready to Calculate Your Deal Terms?